Back to results
US 8,507,215 B2Granted
Diagnostics for membranous nephropathy
AssigneesBoston Medical Center Corporation, Le Centre National De La Recherche Scientifique
InventorsDavid J Salant, Laurence H. Beck, Gerard Lambeau
Life of this patent
Estimating the term…
Abstract
The invention provides immunoassays for detecting serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R) and uses thereof for diagnosis and prognosis evaluation of idiopathic membranous nephropathy (MN).
Claims20
An assay comprising:
- a. measuring a level of antibodies that are reactive to a phospholipase A2 receptor (PLA2R) in a blood sample obtained from a patient who presents at least one symptom of idiopathic membranous nephropathy (MN) for determining the likelihood of idiopathic MN in the patient;
- and
- b. comparing the level of the antibodies in the blood sample with a control data, wherein a detectable increase of at least 10% increase in the antibodies that are reactive to PLA2 in the blood sample over that of the control data indicates the likelihood of MN in the patient.
An assay comprising:
- a. measuring a level of antibodies that are reactive to a phospholipase A2 receptor (PLA2R) in a blood sample obtained from a patient who previously has been successfully treated for idiopathic membranous nephropathy (MN) for determining the likelihood of relapse of idiopathic MN in the patient,
- wherein the level of PLA2R antibodies is measured by the steps comprising:
- contacting the blood sample from the patient with a PLA2R or PLA2R fragment thereof;
- forming an antibody-protein complex between the antibody present in the blood sample with the PLA2R or PLA2R fragment thereof;
- washing to remove any unbound antibody;
- adding a detection antibody that is labeled and is reactive to the antibody from the blood sample;
- washing to remove any unbound labeled detection antibody;
- and
- converting the label to a detectable signal, wherein the detectable signal indicates the level of PLA2R antibodies in the blood sample;
- and
- b. comparing the level of the antibodies in the blood sample with a control data, wherein a detectable increase of at least 10% in the antibodies that are reactive to PLA2R in the blood sample over that of the control data indicates the likelihood of relapse of idiopathic MN.
8 more elements
An assay comprising:
- a. measuring a level of antibodies that are reactive to a phospholipase A2 receptor (PLA2R) in a blood sample obtained from a patient who previously has been successfully treated for idiopathic membranous nephropathy (MN) for determining the likelihood of relapse of idiopathic MN in the patient,
- wherein the level of PLA2R antibodies is obtained by measuring a light scattering intensity resulting from the formation of an antibody-protein complex formed by a reaction of the blood sample with a PLA2R or PLA2R protein fragment thereof, wherein the light scattering intensity indicates the level of PLA2R antibodies in the blood sample;
- and
- comparing the light scattering intensity with a control light scattering intensity data, wherein the light scattering intensity of at least 10% above the control light scattering intensity indicates the likelihood of idiopathic MN relapse in the patient, and wherein the control light scattering intensity is that of PLA2R or PLA2R protein fragment in the absence of blood sample.
1 more element
An assay comprising:
- a. measuring a level of antibodies that are reactive to a phospholipase A2 receptor (PLA2R) in a blood sample obtained from a patient who presents at least one symptom of idiopathic membranous nephropathy (MN) for determining the likelihood of idiopathic MN in the patient;
- b. comparing the level of the antibodies in the blood sample with a control data;
- and
- c. if there is a detectable increase of at least 10% in the antibodies that are reactive to PLA2R in the blood sample over that of a control data, then selecting the patient for treatment for idiopathic MN without subjecting the patient to a kidney biopsy.
1 more element
Dependencies are inferred from the claim text.